Condition: Metastatic Breast Cancer · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
This study is to explore the efficacy and safety of the first-line treatment of HER2 positive recurrent/metastatic breast cancer with Inetetamab combined with Pertuzumab or Pyrotinib combined with chemotherapy, hoping to have better clinical benefits and provide a new treatment mode for targeted treatment.
This description comes directly from the study's public registry record.
Jianli Zhao, Doctor · 15920589334 · zhaojli5@mail.sysu.edu.cn
Ying Wang, Doctor · 13925038181 · yingwang1101@126.com
Always discuss trial participation with your own doctor first.
| Sun Yat sen Memorial Hospital of Sun Yat sen University Shenzhen Shantou Central Hospital | Shanwei, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06641544